All Stories

  1. Development and applications of oncolytic Maraba virus vaccines

    Article • Oncolytic Virotherapy, November 2018, Dove Medical Press

    Dr Jonathan G Pol, Mathieu Crupi, Kyle Stephenson

  2. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

    Article • OncoImmunology, September 2018, Taylor & Francis

    Dr Sergio A Acuna, Dr Jonathan G Pol, Mathieu Crupi, Dr Brian Lichty, Robin Parsons

  3. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

    Article • OncoImmunology, August 2018, Taylor & Francis

    Dr Jonathan G Pol, Mathieu Crupi, Prof. Guido Kroemer

  4. Oncolytic viruses

    Article • Future Virology, June 2018, Future Medicine

    Mathieu Crupi

  5. The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses

    Article • Oncolytic Virotherapy, March 2018, Dove Medical Press

    Mathieu Crupi

  6. Oncolytic Viruses: The Best is Yet to Come

    Article • Current Cancer Drug Targets, January 2018, Bentham Science Publishers

    Mathieu Crupi

  7. Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

    Article • OncoImmunology, December 2017, Taylor & Francis

    Nathalie Labarriere, Dr Frederic Tangy, Dr Jean-Francois Fonteneau, Mathieu Crupi

  8. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

    Article • Oncolytic Virotherapy, January 2015, Taylor & Francis

    Caroline Breitbach, Mathieu Crupi

  9. Cell carriers for oncolytic viruses: current challenges and future directions

    Article • Oncolytic Virotherapy, October 2013, Taylor & Francis

    Mathieu Crupi